Betina Østergaard Eriksen is currently Vice President, Safety Surveillance at Novo Nordisk, where she is responsible for signal management, risk management and aggregate reporting across the product portfolio. She is a registered physician from the University of Copenhagen. Since joining the pharmaceutical industry in 2001, she has been working in different European and global leadership roles across R&D, where she has broad pharmacovigilance experience from almost 15 years in drug safety in different companies.